Clay Siegall: A Champion for Targeted Cancer Therapy

Clay Siegall is a renowned specialist and scholar in cancer research with an impressive record of success in the drive towards developing innovative and effective targeted cancer therapies. However, he is also known for his very informative blog posts. As a blogger, Clay Siegall regularly posts blogs on a wide range of topics that touch the lives of many people around the world. One such interesting and important issue is the recent revival of the reach on the use of stem cells in the treatment of Parkinson’s disease.

Transplanting of stem cells to treat Parkinson’s disease was abandoned several years following failures of the fetal brain stem cells used. While some of the patients benefitted from the pioneering work, other suffered additional symptoms such as uncontrolled movements. The revival of the project by a group of scientists drawn mainly from Europe and the United States is informed by the technological advancements and deeper insight they now have on the procedure. After years of studying the successful cases, the scientists established that there were flaws in the use of the undifferentiated fetal brain stem cells. The cells later differentiated into other cells already in the brain after transplanting therefore leading to the side effects. However, using advanced technologies the scientists who are awaiting the FDA to approve their procedure managed to isolate mature adult stem cells and refined their production of pure lines of dopamine.

Academic and Career Background

Clay Siegall is a graduate of the University of Maryland where he studied for Bachelor of Science in Zoology. It is while at the university that he developed a strong interest in cancer research and treatment after witnessing his relative go through the painful ordeal of conventional cancer therapy. He later studied for his PhD in Genetics at the George Washington University.

After working as a research scientist for several organizations, Clay Siegall cofounded Seattle Genetics in 1998 where he currently serves as the president and chief executive officer. He has overseen significant success at the company including strategic partnerships and raising of millions of dollars in capital to support cancer research and development. His initiatives has seen the company develop an FDA-approved drug, Adcentris for targeted cancer therapy.